{"id":4265,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2020-10-16","marketCap":87.84764099121094,"name":"Aligos Therapeutics Inc","phone":"18004666059","outstanding":78.11000061035156,"symbol":"ALGS","website":"https://www.aligos.com/","industry":"Biotechnology"},"price":14.5725,"year":2024,"month":8,"day":20,"weekday":"Tuesday","title":"Historical P/B Ratio Trends of Aligos Therapeutics Inc","date":"2024-08-20","url":"/posts/2024/08/20/ALGS","content":[{"section":"Introduction","text":"The price-to-book (P/B) ratio is a valuation metric that compares a company's market value per share to its book value per share. It is calculated by dividing the market price per share by the book value per share. The P/B ratio is a useful indicator of how the market values a company relative to its net assets."},{"section":"Historical P/B Ratio Data","text":"Unfortunately, specific historical P/B ratio data for Aligos Therapeutics Inc is not available. As a result, it is not possible to analyze the exact trends in the company's P/B ratio. It is advisable to consult a financial database or reliable sources to obtain the necessary data."},{"section":"Relevance for Investors","text":"Analyzing the historical P/B ratio trends can provide investors with insights into whether Aligos Therapeutics Inc stock is overvalued or undervalued relative to its book value. A high P/B ratio may indicate that the market has high expectations for the company's future growth prospects, potentially making it overvalued. Conversely, a low P/B ratio may suggest undervaluation, presenting an opportunity for investment. However, it is important to consider other factors such as industry dynamics, competitive position, and financial performance when making investment decisions."},{"section":"Conclusion","text":"Unfortunately, without access to specific historical P/B ratio data, a comprehensive analysis of the trends and their relevance for investors cannot be provided. Investors interested in making informed decisions regarding Aligos Therapeutics Inc stock should consult reliable sources or financial databases for accurate and up-to-date P/B ratio information."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1724044320,"headline":"Aligos Therapeutics initiated with bullish view at H.C. Wainwright, here's why","id":129451151,"image":"","symbol":"ALGS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3605717349"},{"category":"company","date":1723791000,"headline":"Aligos Therapeutics trading halted, news pending","id":129423708,"image":"","symbol":"ALGS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3603712581"},{"category":"company","date":1723726800,"headline":"Aligos Therapeutics Announces Reverse Stock Split","id":129391068,"image":"https://media.zenfs.com/en/globenewswire.com/3effef0e914cf3a3df127b306a99de95","symbol":"ALGS","publisher":"Yahoo","summary":"SOUTH SAN FRANCISCO, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will effect a 1-for-25 reverse stock split of its shares of common stock. The reverse stock split will become effective at 12:01 am ET on Monday, August 19, 2024. The Company’s common stock is expected begi","url":"https://finance.yahoo.com/news/aligos-therapeutics-announces-reverse-stock-130000528.html"},{"category":"company","date":1723718880,"headline":"Aligos Therapeutics announces 1-for-25 reverse stock split","id":129387316,"image":"","symbol":"ALGS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3601818735"},{"category":"company","date":1723219211,"headline":"What Makes Aligos Therapeutics (ALGS) a New Buy Stock","id":129265197,"image":"https://media.zenfs.com/en/zacks.com/3cb5117fc22f5e37890d1860dcd61f9f","symbol":"ALGS","publisher":"Yahoo","summary":"Aligos Therapeutics (ALGS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.","url":"https://finance.yahoo.com/news/makes-aligos-therapeutics-algs-buy-160011421.html"},{"category":"company","date":1723147500,"headline":"Aligos Therapeutics Strengthens Board with Two New Independent Directors","id":129245036,"image":"https://media.zenfs.com/en/globenewswire.com/3effef0e914cf3a3df127b306a99de95","symbol":"ALGS","publisher":"Yahoo","summary":"SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the appointment of Heather Preston, M.D. and Margarita Chavez, J.D. as Class II Independent Directors to the Board of Directors, effective August 7, 2024. Dr. Preston will join the Nominating and Corporate Gove","url":"https://finance.yahoo.com/news/aligos-therapeutics-strengthens-board-two-200500586.html"},{"category":"company","date":1723114447,"headline":"Aligos Therapeutics Second Quarter 2024 Earnings: EPS: US$0.032 (vs US$0.43 loss in 2Q 2023)","id":129251201,"image":"https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","symbol":"ALGS","publisher":"Yahoo","summary":"Aligos Therapeutics ( NASDAQ:ALGS ) Second Quarter 2024 Results Key Financial Results Net income: US$5.06m (up from...","url":"https://finance.yahoo.com/news/aligos-therapeutics-second-quarter-2024-105407488.html"},{"category":"company","date":1723088640,"headline":"Aligos Therapeutics Expands Board with New Director Appointments","id":129247900,"image":"","symbol":"ALGS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3592694501"},{"category":"company","date":1723049623,"headline":"Hepatitis B market is ripe for treatment development, says Aligos CEO","id":129225779,"image":"https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/08/liver-disease-image.jpg","symbol":"ALGS","publisher":"Yahoo","summary":"As WHO reports a high HBV burden, Aligos Therapeutics’ CEO highlighted the potential for pharma to address unmet needs.","url":"https://www.pharmaceutical-technology.com/news/hepatitis-b-market-is-ripe-for-treatment-development-says-aligos-ceo/"},{"category":"company","date":1723011900,"headline":"Piper Sandler Keeps Their Buy Rating on Aligos Therapeutics (ALGS)","id":129215153,"image":"","symbol":"ALGS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3589817921"},{"category":"company","date":1722974700,"headline":"Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results","id":129195960,"image":"https://media.zenfs.com/en/globenewswire.com/3effef0e914cf3a3df127b306a99de95","symbol":"ALGS","publisher":"Yahoo","summary":"SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the second quarter 2024. “This quarter we continued to execute on our key clinical programs,” stated Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Offic","url":"https://finance.yahoo.com/news/aligos-therapeutics-reports-recent-business-200500862.html"},{"category":"company","date":1722960300,"headline":"Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results","id":129188353,"image":"","symbol":"ALGS","publisher":"GlobeNewswire","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=bml76ff4ri"},{"category":"company","date":1722917040,"headline":"Aligos Therapeutics reports Q2 EPS 3c, one estimate (16c)","id":129188355,"image":"","symbol":"ALGS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3588811915"},{"category":"company","date":1722916440,"headline":"Aligos Therapeutics GAAP EPS of $0.03 beats by $0.19","id":129188357,"image":"","symbol":"ALGS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3588792859"}]}